Ilya Tsimafeyeu

Summary

Publications

  1. ncbi Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Moscow, Russian Federation
    BJU Int 112:32-8. 2013
  2. doi Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Bazovskayaul 4 1, Moscow, Russian Federation
    Am J Clin Oncol 35:251-4. 2012
  3. doi Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Bazovskaya ul 4 1 office 15, Moscow, Russia
    J Cancer Res Ther 6:575-7. 2010
  4. ncbi OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Bazovskaya ul 4 1 15, Moscow, 125635, Russian Federation
    Invest New Drugs 31:1436-43. 2013
  5. doi Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Moscow, Russia
    Scand J Urol Nephrol 45:190-5. 2011

Detail Information

Publications5

  1. ncbi Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Moscow, Russian Federation
    BJU Int 112:32-8. 2013
    ..To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primary tumours...
  2. doi Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Bazovskayaul 4 1, Moscow, Russian Federation
    Am J Clin Oncol 35:251-4. 2012
    ..Thus, we performed a phase II, multicenter trial of capecitabine in patients with non-clear cell MRCC...
  3. doi Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Bazovskaya ul 4 1 office 15, Moscow, Russia
    J Cancer Res Ther 6:575-7. 2010
    ..Also, we detected high immunohistochemical expression of vascular endothelial growth factor receptors 1 and 2 in the cytoplasm and nuclei of tumor cells...
  4. ncbi OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Bazovskaya ul 4 1 15, Moscow, 125635, Russian Federation
    Invest New Drugs 31:1436-43. 2013
    ..OM-RCA-01 is being developed clinically as an intravenous therapy for the treatment of clear cell RCC...
  5. doi Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
    Ilya Tsimafeyeu
    Kidney Cancer Research Bureau, Moscow, Russia
    Scand J Urol Nephrol 45:190-5. 2011
    ..Membrane antigens such as FGFR expressed in RCC are attractive targets for new therapeutic and diagnostic applications. This study evaluated the expression of FGFR1 and FGFR2 in RCC...